Double-blinded infliximab dose escalation in patients with rheumatoid arthritis
about
Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritisSystematic review of tocilizumab for rheumatoid arthritis: a new biologic agent targeting the interleukin-6 receptor.Dose escalation of certolizumab pegol from 200 mg to 400 mg every other week provides no additional efficacy in rheumatoid arthritis: an analysis of individual patient-level data.Infliximab concentration monitoring improves the control of disease activity in rheumatoid arthritisEconomic evaluation of anti-TNF agents for patients with rheumatoid arthritis in Greece.Baseline tumour necrosis factor alpha levels predict the necessity for dose escalation of infliximab therapy in patients with rheumatoid arthritis.Primary lack of efficacy of infliximab therapy for rheumatoid arthritis: pharmacokinetic characterization and assessment of switching to tocilizumab.Current status and future prospects for biologic treatments of psoriasis.Effect of Infliximab Dose Increase in Rheumatoid Arthritis at Different Trough Concentrations: A Cohort Study in Clinical Practice Conditions.Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate.Translating co-stimulation blockade into clinical practice.Psoriatic arthritis: genetic susceptibility and pharmacogenetics.Infliximab therapy for intestinal, neurological, and vascular involvement in Behcet disease: Efficacy, safety, and pharmacokinetics in a multicenter, prospective, open-label, single-arm phase 3 study.Infliximab in the treatment of rheumatoid arthritisImpact of trough serum level on radiographic and clinical response to infliximab plus methotrexate in patients with rheumatoid arthritis: results from the RISING study.'I'm hurting, I want to kill myself': rheumatoid arthritis flare is more than a high joint count--an international patient perspective on flare where medical help is sought.Therapeutic drug monitoring in rheumatic diseases: utile or futile?Dose optimization of infliximab in patients with rheumatoid arthritis.Dose modification of anti-TNF in rheumatoid arthritis and estimated economical impact: a review of observational studies.Clinical Pharmacokinetics and Pharmacodynamics of Monoclonal Antibodies Approved to Treat Rheumatoid Arthritis.Therapeutic drug monitoring of monoclonal antibodies in inflammatory and malignant disease: Translating TNF-α experience to oncology.Comparison of immunogenicity test methods used in clinical studies of infliximab and its biosimilar (CT-P13).Efficacy and safety of dose escalation of infliximab therapy in Japanese patients with psoriasis: Results of the SPREAD study.The underlying inflammatory chronic disease influences infliximab pharmacokinetics.High titers of both rheumatoid factor and anti-CCP antibodies at baseline in patients with rheumatoid arthritis are associated with increased circulating baseline TNF level, low drug levels, and reduced clinical responses: a post hoc analysis of theDramatic impact of a Psoriasis Area and Severity Index 90 response on the quality of life in patients with psoriasis: an analysis of Japanese clinical trials of infliximab.Anti-TNF treatments in rheumatoid arthritis: economic impact of dosage modification.Durability of infliximab dose intensification in Crohn's disease.Comparing biosimilar SB2 with reference infliximab after 54 weeks of a double-blind trial: clinical, structural and safety results.Patient-self assessment of flare in rheumatoid arthritis: translation and reliability of the Flare instrument.Efficacy and safety of infliximab: A comparison with other biological disease-modifying anti-rheumatic drugs.Immunoassay methods used in clinical studies for the detection of anti-drug antibodies to adalimumab and infliximab.
P2860
Q21134808-7FA9A07D-2B29-4D80-9E34-27401694A7E2Q33400381-1562EEF3-963C-4742-8E09-7398771E1B28Q33870043-B651F4AF-5436-4622-9868-87D738E31147Q34413316-431D9383-78AD-4087-A3C9-113B76D11802Q35001257-5E113B3F-3334-400F-B384-A2B56BA761FBQ35012157-F295F099-DCF6-491B-9ABA-9F59F69BA04BQ35610243-A735AA14-EBDB-4D2F-8D31-45C15712D7AFQ36057909-12FA94FA-311A-4B17-BAAE-1313A827EA9BQ36133890-1CB1D640-A69E-4C2F-A440-1C56FB86642AQ36930704-19A7E1BE-7E50-49D1-92E1-A82ECE144159Q36972500-FA9AF845-3E09-4772-966F-1DFF68A69B7AQ37120837-5BEE11D8-12E4-46B2-9F92-5F4FA724C66FQ37205638-11689DAE-7885-48F1-A657-A93E87F6B5FBQ37303230-8F76E497-FF12-4B76-94FA-925FF2118EC0Q37380288-AE35668F-DC82-40FE-8243-732BE368F413Q37874841-17B81F2F-0078-4B3D-910C-9F2809932A31Q38160305-A7C85FCB-637A-49FE-B6AE-26FA45D75E6BQ38182728-8CFD89CD-A909-4C25-A6DC-48D4359374D1Q38306139-34FEEAE5-D92A-49CD-B3D4-353A73C85EF0Q38540353-8B4606D0-4E9D-4F06-88DD-732C8810115AQ38564877-0153D11C-0FF5-4051-960C-7E007C5BFCACQ38591278-07EEC0C0-0149-49BD-8A95-2DA320A19AFEQ40437510-FA5A59D9-9ADA-438C-AE95-AD3AF3912CBCQ41416145-8B477654-5800-4269-B4D5-C2BE2AD1484EQ41595373-7E97DBF3-4883-4E61-AD2E-24820C69E9C5Q44456581-AC90D004-AFA7-4B85-A83F-58058A4C19F3Q44790776-B6C485F0-7D48-4084-8497-C8626DE1E7E3Q46354771-160A6CA1-3289-4CB2-9760-EDFD04338597Q47731175-BE9E308C-76A7-475E-930A-15A4A6ACDDA3Q48046367-615D967F-81DA-447C-9F8A-ADEA2BA780F5Q48253106-2EE25425-D582-407C-BBCC-C121E4ED0B99Q50065301-02B071CC-58B7-42EC-915A-62F5D08F5E7B
P2860
Double-blinded infliximab dose escalation in patients with rheumatoid arthritis
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 28 March 2007
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Double-blinded infliximab dose escalation in patients with rheumatoid arthritis
@en
Double-blinded infliximab dose escalation in patients with rheumatoid arthritis.
@nl
type
label
Double-blinded infliximab dose escalation in patients with rheumatoid arthritis
@en
Double-blinded infliximab dose escalation in patients with rheumatoid arthritis.
@nl
prefLabel
Double-blinded infliximab dose escalation in patients with rheumatoid arthritis
@en
Double-blinded infliximab dose escalation in patients with rheumatoid arthritis.
@nl
P2093
P2860
P356
P1476
Double-blinded infliximab dose escalation in patients with rheumatoid arthritis
@en
P2093
Alberto Berman
Carrie Wagner
Daniel Baker
David Yocum
Ingrid Strusberg
Mahboob U Rahman
Piet Geusens
Rene Westhovens
P2860
P304
P356
10.1136/ARD.2006.065995
P407
P577
2007-03-28T00:00:00Z